|
1
|
Ye M, Fu S, Pi R and He F:
Neuropharmacological and pharmacokinetic properties of berberine: A
review of recent research. J Pharm Pharmacol. 61:831–837. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Song YC, Lee Y, Kim HM, Hyun MY, Lim YY,
Song KY and Kim BJ: Berberine regulates melanin synthesis by
activating PI3K/AKT, ERK and GSK3β in B16F10 melanoma cells. Int J
Mol Med. 35:1011–1016. 2015.PubMed/NCBI
|
|
3
|
Saha P, Bhattacharjee S, Sarkar A, Manna
A, Majumder S and Chatterjee M: Berberine chloride mediates its
anti-leishmanial activity via differential regulation of the
mitogen activated protein kinase pathway in macrophages. PLoS One.
6:e184672011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chi L, Peng L, Pan N, Hu X and Zhang Y:
The anti-atherogenic effects of berberine on foam cell formation
are mediated through the upregulation of sirtuin 1. Int J Mol Med.
34:1087–1093. 2014.PubMed/NCBI
|
|
5
|
Hu Z, Jiao Q, Ding J, Liu F, Liu R, Shan
L, Zeng H, Zhang J and Zhang W: Berberine induces dendritic cell
apoptosis and has therapeutic potential for rheumatoid arthritis.
Arthritis Rheum. 63:949–959. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cui G, Qin X, Zhang Y, Gong Z, Ge B and
Zang YQ: Berberine differentially modulates the activities of ERK,
p38 MAPK, and JNK to suppress Th17 and Th1 T cell differentiation
in type 1 diabetic mice. J Biol Chem. 284:28420–28429. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Qin X, Guo BT, Wan B, Fang L, Lu L, Wu L,
Zang YQ and Zhang JZ: Regulation of Th1 and Th17 cell
differentiation and amelioration of experimental autoimmune
encephalomyelitis by natural product compound berberine. J Immunol.
185:1855–1863. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yang Y, Qi J, Wang Q, Du L, Zhou Y, Yu H,
Kijlstra A and Yang P: Berberine suppresses Th17 and dendritic cell
responses. Invest Ophthalmol Vis Sci. 54:2516–2522. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yang P, Fang W, Meng Q, Ren Y, Xing L and
Kijlstra A: Clinical features of chinese patients with Behçet's
disease. Ophthalmology. 115:312–318. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Amadi-Obi A, Yu CR, Liu X, Mahdi RM,
Clarke GL, Nussenblatt RB, Gery I, Lee YS and Egwuagu CE: TH17
cells contribute to uveitis and scleritis and are expanded by IL-2
and inhibited by IL-27/STAT1. Nat Med. 13:711–718. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chi W, Yang P, Li B, Wu C, Jin H, Zhu X,
Chen L, Zhou H, Huang X and Kijlstra A: IL-23 promotes
CD4+ T cells to produce IL-17 in Vogt-Koyanagi-Harada
disease. J Allergy Clin Immunol. 119:1218–1224. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Peng Y, Han G, Shao H, Wang Y, Kaplan HJ
and Sun D: Characterization of IL-17+ interphotoreceptor
retinoid-binding protein-specific T cells in experimental
autoimmune uveitis. Invest Ophthalmol Vis Sci. 48:4153–4161. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Luger D, Silver PB, Tang J, Cua D, Chen Z,
Iwakura Y, Bowman EP, Sgambellone NM, Chan CC and Caspi RR: Either
a Th17 or a Th1 effector response can drive autoimmunity:
Conditions of disease induction affect dominant effector category.
J Exp Med. 205:799–810. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liu X, Yang P, Lin X, Ren X, Zhou H, Huang
X, Chi W, Kijlstra A and Chen L: Inhibitory effect of Cyclosporin A
and corticosteroids on the production of IFN-gamma and IL-17 by T
cells in Vogt-Koyanagi-Harada syndrome. Clin Immunol. 131:333–342.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mathur AN, Chang HC, Zisoulis DG,
Stritesky GL, Yu Q, O'Malley JT, Kapur R, Levy DE, Kansas GS and
Kaplan MH: Stat3 and Stat4 direct development of IL-17-secreting Th
cells. J Immunol. 178:4901–4907. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tulunay A, Dozmorov MG, Ture-Ozdemir F,
Yilmaz V, Eksioglu-Demiralp E, Alibaz-Oner F, Ozen G, Wren JD,
Saruhan-Direskeneli G, Sawalha AH and Direskeneli H: Activation of
the JAK/STAT pathway in Behcet's disease. Genes Immun. 16:170–175.
2014.PubMed/NCBI
|
|
17
|
Qi J, Yang Y, Hou S, Qiao Y, Wang Q, Yu H,
Zhang Q, Cai T, Kijlstra A and Yang P: Increased Notch pathway
activation in Behçet's disease. Rheumatology (Oxford). 53:810–820.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Criteria for diagnosis of Behçet's
disease, . International Study Group for Behçet's Disease. Lancet.
335:1078–1080. 1990.PubMed/NCBI
|
|
19
|
Rickham PP: Human experimentation. Code of
ethics of the world medical association. Declaration of Helsinki.
Br Med J. 2:1771964. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ma X, Jiang Y, Wu A, Chen X, Pi R, Liu M
and Liu Y: Berberine attenuates experimental autoimmune
encephalomyelitis in C57 BL/6 mice. PLoS One. 5:e134892010.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Marinova EK, Nikolova DB, Popova DN,
Gallacher GB and Ivanovska ND: Suppression of experimental
autoimmune tubulointerstitial nephritis in BALB/c mice by
berberine. Immunopharmacology. 48:9–16. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gupta SK, Agarwal R, Srivastava S, Agarwal
P, Agrawal SS, Saxena R and Galpalli N: The anti-inflammatory
effects of Curcuma longa and Berberis aristata in endotoxin-induced
uveitis in rabbits. Invest Ophthalmol Vis Sci. 49:4036–4040. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Na SY, Park MJ, Park S and Lee ES:
Up-regulation of Th17 and related cytokines in Behçet's disease
corresponding to disease activity. Clin Exp Rheumatol. 31(3): Suppl
77. 32–40. 2013.PubMed/NCBI
|
|
24
|
Chi W, Yang P, Zhu X, Wang Y, Chen L,
Huang X and Liu X: Production of interleukin-17 in Behcet's disease
is inhibited by cyclosporin A. Mol Vis. 16:880–886. 2010.PubMed/NCBI
|
|
25
|
Hedegaard CJ, Krakauer M, Bendtzen K,
Sorensen PS, Sellebjerg F and Nielsen CH: The effect of
beta-interferon therapy on myelin basic protein-elicited
CD4+ T cell proliferation and cytokine production in
multiple sclerosis. Clin Immunol. 129:80–89. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Xu L, Liu Y and He X: Inhibitory effects
of berberine on the activation and cell cycle progression of human
peripheral lymphocytes. Cell Mol Immunol. 2:295–300.
2005.PubMed/NCBI
|
|
27
|
Jiang XW, Zhang Y, Zhu YL, Zhang H, Lu K,
Li FF and Peng HY: Effects of berberine gelatin on recurrent
aphthous stomatitis: A randomized, placebo-controlled, double-blind
trial in a Chinese cohort. Oral Surg Oral Med Oral Pathol Oral
Radiol. 115:212–217. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Pang B, Zhao LH, Zhou Q, Zhao TY, Wang H,
Gu CJ and Tong XL: Application of berberine on treating type 2
diabetes mellitus. Int J Endocrinol. 2015:9057492015.PubMed/NCBI
|
